X-Rx is an early stage biotech company focused on the development of small molecule medicines in inflammation, fibrosis and oncology.
X-Rx combines the power of DNA-encoded libraries with a virtual
development model to discover novel therapeutics for difficult to treat diseases.
Founded in 2012 as a spin out of X-Chem, X-Rx is an early stage biotech company with more than 80 years of combined drug discovery and development experience. X-Rx is focused on the development of small molecule medicines in inflammation, fibrosis and oncology
The X-Rx Advantage
X-Rx holds a collection of high-value targets coupled with access to DNA-encoded libraries and strong competencies in structure-based drug design. X-Rx has the ability to quickly identify tractable lead series on a wide range of targets.
The X-Rx Pipeline
Our portfolio includes our lead program X-165, a novel autotaxin inhibitor, being developed for multiple indications in fibrosis and targets across a number of families with multiple series of chemical starting points.
X-Rx Announces Completion of IND-enabling Studies with X-165 for the Treatment of Idiopathic Pulmonary Fibrosis and other Fibrotic Indications
X-Rx, Inc., a privately held biotechnology company focused on applying its innovative drug development capabilities to the generation of novel small molecule therapeutics, today announced that it has completed IND-enabling studies with X-165, a potent orally available inhibitor of autotaxin, for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic indications.